Bioorganic and Medicinal Chemistry p. 5780 - 5791 (2018)
Update date:2022-08-15
Topics:
Guo, Bin
Guo, Shimeng
Huang, Jing
Li, Jingya
Li, Jia
Chen, Qian
Zhou, Xianli
Xie, Xin
Yang, Yushe
GPR40 has become a new potential therapeutic target for the treatment of diabetes due to its role in mediating the enhancement of glucose-stimulated insulin secretion in pancreatic β cells with a low risk of hypoglycemia. As an effort to extend the chemical space and identify structurally distinct GPR40 agonists with improved liver safety, a novel series of fused-ring phenyl propanoic acid analogues were designed. Comprehensive structure-activity relationship studies around novel scaffolds were conducted and led to several analogues exhibited potent GPR40 agonistic activities and high selectivity against other fatty acid receptors. Further evaluation of pharmacokinetic (PK) profiles and in vivo efficacy identified compound 40a with excellent PK properties and significant glucose-lowering efficacy during an oral glucose tolerance test. In addition, compound 40a displayed lower hepatobiliary transporter inhibition and favorable druggability. All results indicate that compound 40a is a promising candidate for further development.
View MoreContact:+33-5-34012600
Address:28 ZA des Pignès
RongCheng Tianyu Technology Co.,Ltd.
Contact:86-631-7519595
Address:220Ping Donghai Road RongChengCity,ShangDong Province China
Engineering Research Center of Pesticide, Heilongjiang Province
Contact:+86-451-86609001
Address:No.74 of Xuefu Road, Nangang District,
Hangzhou Pharma & Chem Co.,Ltd.
Contact:+86-571-87040515
Address:No,139Qingchun Rd
Jining Shengrun Chemical Industry Co., Ltd.
Contact:+86-537-7121666 ,
Address:West Ring Road,Wenshang County Shandong Province
Doi:10.1021/jo01296a005
(1980)Doi:10.1248/cpb.32.3441
(1984)Doi:10.1016/j.jorganchem.2004.03.042
(2004)Doi:10.1021/jm100817f
(2010)Doi:10.1021/jo01296a003
(1980)Doi:10.1134/S0023158410040154
(2010)